biopharmadive.com
Sanofi, Teva add to case for new bowel disease drug
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if later trials confirm benefit and safety.
Adults with Crohn’s disease or ulcerative colitis, patients who have tried advanced therapies, clinicians treating IBD, and researchers following emerging biologic therapies.
What To Know
What to Know Sanofi and Teva presented additional Phase 2b data for their investigational TL1A-targeting drug duvakitug at the ECCO congress.
The results reported higher rates of clinical response, remission and endoscopic improvement versus placebo in both ulcerative colitis and Crohn’s disease groups, with the companies characterizing the treatment as generally well tolerated and without serious adverse events.
The companies highlighted that a higher dose helped about half of patients meet the trial’s primary endpoint at week 14 in each disease cohort, compared with lower placebo response rates. The firms and analysts say these mid-stage data support moving duvakitug into a Phase 3 program planned to begin later in the year.
Why this matters Duvakitug is part of a new class of drugs that target TL1A, a protein linked to intestinal inflammation. These Phase 2b results are the first randomized TL1A data reported in Crohn’s disease and add to growing evidence that TL1A inhibitors could be effective for some people with IBD.
Next steps and caveats This is mid-stage data and not definitive proof of superiority over other emerging IBD drugs; head-to-head comparisons and Phase 3 results are needed. Safety and effectiveness in broader, more diverse patient populations will be evaluated in upcoming trials.
These are mid-stage (Phase 2b) trial results presented at a medical congress; they support moving into Phase 3 testing but do not establish long-term safety or comparative effectiveness. The article is a news summary and cites analyst commentary.
